During the corresponding time, Dermtech Inc recorded a revenue increase by 6.79 % year on year, sequentially revenue fell by -5.38 %. While revenue at the Dermtech Inc 's corporate clients
Dermtech Inc's Comment on Sales, Marketing and Customers
The company serves approximately 13,000 healthcare professionals specializing in dermatology in the United States. Its customer base is segmented into primarily cosmetic practices (10-15%), mixed medical and cosmetic practices (50-75%), and medical-only practices (15-25%). The company focuses on medical dermatology services, community dermatology practices, multi-site group practices (approximately 25%), and large integrated dermatology networks (approximately 15%). It also considers targeting the primary care market through distribution partners with experience in diagnostics or genomics. The company has an exclusive agreement with Sonora Quest as the reference laboratory in Arizona. Marketing efforts include physician education, dermatology symposia, publications, peer-to-peer education, and participation in dermatology conferences. These efforts are supported by key opinion leaders, including former American Academy of Dermatology (AAD) presidents and experts in melanoma, skin cancer, and inflammatory diseases. The company plans to expand internationally to regions with high melanoma and skin cancer incidence, such as Australia and Western Europe, potentially through distribution partners after establishing its presence in the U.S. market.
In a recent press release, DermTech, a prominent player in precision dermatology leveraging non-invasive skin genomics technology, announced that its special committee of board directors has engaged TD Cowen to explore strategic alternatives with the goal of maximizing stockholder value. This move reflects the company s commitment to enhancing its position in the market and furthering its growth potential.Potential strategic alternatives being considered encompass a wide range of possibilities, such as acquisition, merger, reverse merger, business combination, sale of assets, and licensing agreements. DermTech is leaving no stone unturned as it seeks opportunities that align with its overarching mission and ...
SAN DIEGO - DermTech, a trailblazer in precision dermatology, revealed today its plans to delve into strategic alternatives to increase stockholder value. The special committee of the company s board of directors has enlisted the expertise of TD Cowen to lead the exploration process. DermTech aims to leverage its groundbreaking non-invasive skin genomics technology to unlock new possibilities and forge ahead in the dermatology field.The potential strategies that DermTech may explore or evaluate as part of this process comprise an acquisition, merger, reverse merger, business combination, sale of assets, and licensing opportunities. By engaging in a rigorous evaluation of these options, DermTech is diligently...
DermTech, a leading player in precision dermatology leveraging non-invasive skin genomics technology, has recently shared promising results from its Trust 2 Study. This study evaluated the foundational gene expression assay component of their DermTech Melanoma Test (DMT) in a real-world clinical setting. The positive outcomes of the study confirm the remarkable clinical utility of DMT in ruling out melanoma, with a high negative predictive value.
DermTech s Trust 2 Study aimed to assess the effectiveness of DMT s gene expression assay component in accurately identifying melanoma in a real-world clinical environment. The positive topline results from this study serve as a signifi...
Dermtech Inc’s Comment on Sales, Marketing and Customers
The company serves approximately 13,000 healthcare professionals specializing in dermatology in the United States. Its customer base is segmented into primarily cosmetic practices (10-15%), mixed medical and cosmetic practices (50-75%), and medical-only practices (15-25%). The company focuses on medical dermatology services, community dermatology practices, multi-site group practices (approximately 25%), and large integrated dermatology networks (approximately 15%). It also considers targeting the primary care market through distribution partners with experience in diagnostics or genomics. The company has an exclusive agreement with Sonora Quest as the reference laboratory in Arizona. Marketing efforts include physician education, dermatology symposia, publications, peer-to-peer education, and participation in dermatology conferences. These efforts are supported by key opinion leaders, including former American Academy of Dermatology (AAD) presidents and experts in melanoma, skin cancer, and inflammatory diseases. The company plans to expand internationally to regions with high melanoma and skin cancer incidence, such as Australia and Western Europe, potentially through distribution partners after establishing its presence in the U.S. market.
Sources:
Dermtech Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Dermtech Inc’s corporate clients.
For your research, we’ve provided 9 tables on Dermtech Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
